Sermorelin is the aristocrat of the GH-peptide menu: the only one that was an actual FDA-approved drug. Geref treated pediatric growth-hormone deficiency from 1997 until its 2008 discontinuation - for commercial reasons, not safety. That pedigree is why sermorelin survived the compounding crackdowns that killed ipamorelin's lane, and why clinics lean on it. What the pedigree doesn't cover is the use it's actually sold for.
What sermorelin is
Sermorelin is GHRH(1-29) - the first 29 amino acids of natural growth-hormone-releasing hormone, the fragment carrying full biological activity. Unlike ghrelin-mimetics (ipamorelin), it works through the GHRH receptor, producing GH release that stays under the body's own somatostatin feedback - a genuinely more physiological mechanism, and the basis of its 'works with your body' marketing.
The Geref history - and its limits
FDA approval (1997) was for diagnosing and treating growth-hormone deficiency in children. EMD Serono discontinued Geref in 2008 as recombinant GH won that market. Two consequences follow. Legally: a formerly approved substance occupies the most defensible compounding position of any GH peptide - prescriptions via 503A pharmacies persist where state boards allow. Evidentially: nothing in the pediatric GHD dossier tested what clinics sell today - nightly sermorelin for adult body composition, sleep, and aging. That use has never had its trial.
What adult use actually rests on
- Documented: sermorelin raises GH and IGF-1 in adults - hormone-level effects, replicated.
- Small and old: a handful of modest studies in aging adults (IGF-1 restoration, some body-composition signals) - suggestive, underpowered, never followed by definitive trials.
- Absent: controlled evidence for the sold outcomes - fat loss, muscle, sleep quality, 'healthy aging' - at clinic protocols.
The dosage math
Clinic protocols run 200-500 mcg subcutaneously at night (timed to the natural GH pulse in early sleep). Compounded vials vary widely - 2, 5, 9, 15 mg - so the arithmetic matters: a 9 mg vial with 3 ml of bacteriostatic water is 3 mg/ml, making 300 mcg = 0.1 ml = 10 units. The sermorelin calculator runs your actual label numbers.
Sermorelin vs tesamorelin: the honest comparison clinics avoid
Tesamorelin is the same mechanism (stabilized GHRH analog) with what sermorelin lacks: a current FDA approval and controlled trials showing visceral-fat reduction. It costs several times more. When a clinic offers sermorelin as 'the affordable GHRH', the accurate translation is: the one without the evidence, at the price that reflects it. Our tesamorelin guide covers the strong half of the pair.
Frequently asked questions
Is sermorelin FDA approved?
It was - as Geref, for pediatric growth-hormone deficiency, from 1997 until its commercial discontinuation in 2008. No current FDA-approved sermorelin product exists; today's availability runs through compounding pharmacies under prescription, a lane its approval history keeps defensible.
Does sermorelin work for anti-aging or weight loss?
It reliably raises GH/IGF-1. The outcomes it's sold for - fat loss, muscle, sleep, longevity - rest on small, old, suggestive studies and have never been confirmed in adequately powered trials. Hormone movement is documented; benefit is assumed.
Why is sermorelin taken at night?
Natural GH secretion peaks in early deep sleep; dosing GHRH before bed rides that physiology rather than fighting it. It's a rational protocol design inherited from the pediatric literature - rationale, again, not outcome proof for adult use.
How many units is 300 mcg of sermorelin?
Entirely vial-dependent: 9 mg in 3 ml (3 mg/ml) makes 300 mcg = 10 units; 5 mg in 2 ml (2.5 mg/ml) makes it 12 units. Always compute from your pharmacy's label - compounded concentrations vary more for sermorelin than any other GH peptide.